Blood test 4 EDTA tubes
PreclinicalBiologic
Blood test 4 EDTA tubes is one of 64 biologic programs targeting Lung Cancer. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
63
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
686 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Libtayo
RegeneronPreclinical
Talzenna
PfizerPreclinical
Folvite
Eli LillyPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
Paclitaxel and Carboplatin
Bristol-Myers SquibbPreclinical
Rilotumumab
AmgenPreclinical
Acupan
YYonsei University
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
COVID-19 Vaccine
ModernaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Blood test 4 EDTA tubes. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Grenoble